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a b s t r a c t
Helicobacter pylori, a spiral-shaped Gram-negative bacterium, has been classiﬁed as a class
I carcinogen by the World Health Organization and recognized as the causative agent for
peptic ulcers, duodenal ulcer, gastritis, mucosa-associated lymphoid tissue lymphomas,
and gastric cancer. Owing to their alarming rate of drug resistance, eradication of H.
pylori remains a global challenge. Triple therapy consisting of a proton pump inhibitor,
clarithromycin, and either amoxicillin or metronidazole, is generally the recommended
standard for the treatment of H. pylori infection. Complementary and alternative medicines
have a long history in the treatment of gastrointestinal ailments and various compounds
has been tested for anti-H. pylori activity both in vitro and in vivo; however, their successful
use in human clinical trials is sporadic. Hence, the aim of this review is to analyze the role
of some well-known natural products that have been tested in clinical trials in preventing,
altering, or treating H. pylori infections. Whereas some in vitro and in vivo studies in the
literature have demonstrated the successful use of a few potential natural products for the
treatment of H. pylori-related infections, others indicate a need to consider natural products,
with or without triple therapy, as a useful alternative in treating H. pylori-related infections.
Thus, the reported mechanisms include killing of H. pylori urease inhibition, induction
of bacterial cell damage, and immunomodulatory effect on the host immune system.
Furthermore, both in vitro and in vivo studies have demonstrated the successful use of some
potential natural products for the treatment of H. pylori-related infections. Nevertheless,
the routine prescription of potential complementary and alternative medicines continuesto be restrained, and evidence on the safety and efﬁcacy of the active compounds remains
a subject of ongoing debate.
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Table 1 – PubMed
Keywords used for search with article type as
clinical trial
Number of
articles
(Helicobacter pylori) 2935
(Helicobacter pylori) AND herb 1
(Helicobacter pylori) AND plant 45
(Helicobacter pylori) AND extract 9
(Helicobacter pylori) AND (complementary medicine) 27
(Helicobacter pylori) AND (traditional medicine) 12
(Helicobacter pylori) AND (folk medicine) 12
(Helicobacter pylori) AND (oriental medicine) 3
(Helicobacter pylori) AND [herb OR plant OR extract 68
and Scopus databases, we found that only olive oil, Nigella
sativa or caraway, mastic gum, broccoli, cranberry, Prunus112
1. Introduction
The relationship betweenHelicobacter pylori and gastric pathol-
ogywasdescribedabout 30 years agobyWarrenandMarshall.1
Since then,H. pylorihas been recognized as the causative agent
for peptic ulcers, duodenal ulcer, gastritis, dyspepsia, mucosa-
associated lymphoid tissue lymphomas, and gastric cancer.
Although numerous natural products are used in traditional
medicine for the treatment of bacterial infections, the ﬁrst
report on the anti-H. pylori activity of plant products was pub-
lished only 8 years after its discovery.2 Since then, the anti-H.
pylori activity of different plant products or extracts has been
rigorously tested both in vitro and in vivo in animal models.
Triple therapy, which comprises two antibiotics and a pro-
ton pump inhibitor, is a conventionally effective treatment
for H. pylori infections. However, the prolonged use of these
antibiotics can lead to antibiotic resistance in the infectious
organisms and also alter the normal biota of the gastrointesti-
nal system. Use of alternative medicines has been reported to
alleviate the problemsof antibiotic resistancewhile effectively
eliminating the pathogens. There are several available reports
on the anti-H. pylori activity of natural products in certain
databases of academic journals such as PubMed and Scopus,
but paradoxically only a few articles are available based on the
clinical reports. On mining the list of available clinical reports,
it was surprising to observe that most of the natural prod-
ucts that have been extensively reported in in vitro or in vivo
systems were not scaled up to clinical trials and offered no
clue on their safety proﬁles. Although natural products are
generally considered safe under some permitted dosage rates,
their use can be considered as a dietary supplement or an
additive therapy. This review was undertaken to assess sev-
eral selected natural products (Fig. 1) exhibiting anti-H. pylori
activity, which have been tested in preclinical and clinical tri-
als.
Fig. 1 – Commonly known naturalOR (complementary medicine) OR (traditional
medicine) OR (folk medicine) OR (oriental
medicine)]
2. Search strategy
Because our focus for this review article is to look for the
natural products that were tested at clinical settings for anti-
H. pylori activity, our initial search was made in the PubMed
and Scopus databases and restricted to “clinical trials” alone.
While searching in the PubMed, we included the option “clini-
cal trial” in the search as PubMed allows restricting the search
based on article types. However, this option is not available
with Scopus, and hence the term “clinical trial” was included
in the keyword. The search was done considering the differ-
ent terminologies that have been used in the literature for
the study on natural products, and the details of search cri-
teria and the outcome of the search in PubMed and Scopus
databases are summarized in Tables 1 and 2, respectively. On
careful analysis of the “clinical trial” report in both PubMedmume, cinnamon, propolis, and curcumin were suitable for
this review as these were tested at in vitro or in vivo level and
products – bench to bedside.
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Table 2 – Scopus
Keywords used for search Number of
articles
[TITLE-ABS-KEY(“helicobacter pylori”) AND TITLE-ABS-KEY(“clinical trial”)] 5392
[TITLE-ABS-KEY(“helicobacter pylori”) AND TITLE-ABS-KEY(“clinical trial”) AND TITLE-ABS-KEY(herb)] 8
[TITLE-ABS-KEY(“helicobacter pylori”) AND TITLE-ABS-KEY(“clinical trial”) AND TITLE-ABS-KEY(plant)] 78
[TITLE-ABS-KEY(“helicobacter pylori”) AND TITLE-ABS-KEY(“clinical trial”) AND TITLE-ABS-KEY(extract)] 105
[TITLE-ABS-KEY(“helicobacter pylori”) AND TITLE-ABS-KEY(“clinical trial”) AND TITLE-ABS-KEY (complementary medicine)] 8
[TITLE-ABS-KEY(“helicobacter pylori”) AND TITLE-ABS-KEY(“clinical trial”) AND TITLE-ABS-KEY (traditional medicine)] 23
[TITLE-ABS-KEY(“helicobacter pylori”) AND TITLE-ABS-KEY(“clinical trial”) AND TITLE-ABS-KEY (folk medicine)] 2
[TITLE-ABS-KEY(“helicobacter pylori”) AND TITLE-ABS-KEY(“clinical trial”) AND TITLE-ABS-KEY (oriental medicine)] 0
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lso at clinical conditions. Although a few others, such as pep-
ermint oil and Chinese herbal medicine, have been reported
n clinical trials, theywere excluded from this review either for
he reason that the articles are not available in the English lan-
uage or the datawere found to be inappropriate or unsuitable
or the current review.
. Olive oil
live oil is produced by pressing whole olives, and is com-
only used in cooking, cosmetics, pharmaceuticals, and
oaps. Romero et al3 examined the effect of olive oil on eight
ifferent H. pylori clinical isolates, including three antibiotic-
esistant strains, andobserved thepotent anti-H. pylori activity
f olive oil against all the tested strains. In addition to the
ntibacterial activity, it is also worth noting that the active
henolic compounds in olive oil can remain stable for sev-
ral hours under harsh acidic environments. Among the
arious phenolic compounds tested, the dialdehydic form of
ecarboxymethyl ligstroside aglycone showed the strongest
actericidal effect at a very low concentration of 1.3g/mL.
ontrary to the ﬁndings of Romero et al,3 Preuss et al4 reported
hat olive oil does not exert antibacterial effect against H.
ylori; this conﬂicting ﬁnding could be attributable to the dif-
erence in the use of olive oil, which was used only as a carrier
or other herbal oils and not as the principal component in the
tudy of Preuss et al.4
Based on the results of previous studies, Castro et al5
erformed two different pilot clinical studies comprising 30
articipants, identiﬁed as H. pylori-positive, per trial. In the
rst trial, all 30 individuals received 30g of olive oil at two
ifferent time intervals—initially, washed virgin olive oil was
dministered for 14 days and then, after a 1-month gap,
nwashed virgin olive oil was administered for 14 days. The
esearchers found that H. pylori infection was eliminated in
ight of the 30 (27%) individuals after 4–6 weeks from the ﬁrst
linical intervention, and at the end of the study, 12 of the 30
ndividuals did not show H. pylori infection. This result indi-
ates that olive oil had cleared the H. pylori infection in 40% of
he cases on completion of the treatment protocol. In the sec-
nd clinical intervention, 30 g of different virgin olive oils was
dministered for 14 days to 30 H. pylori-positive individuals.
nly three of the 30 (10%) individuals were H. pylori-negative
fter 4–6 weeks, and ﬁve of the 30 individuals (11%) were neg-
tive in 24–72hours after administration of the last oil dose.5AND TITLE-ABS-KEY(herb) OR
omplimentary medicine”) OR
e”) OR TITLE-ABS-KEY(“oriental medicine”)]
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The results of the twoabove-mentioned interventions indicate
that although virgin olive oil could exert appreciable anti-H.
pylori activity in vitro, it only showed a moderate effectiveness
in eradicating H. pylori in clinical settings. However, further
appropriate clinical studies, particularly with longer periods,
different administration conditions, and different types of
olive oils, are required to verify these ﬁndings.
4. Nigella Sativa or black caraway
The seeds of N. sativa, an annual ﬂowering plant native to the
south and southwest Asia, have been valued for their healing
properties since time immemorial.6 Many active ingredients
isolated from N. sativa have been shown to exhibit various
pharmacological effects such as immune stimulation, anti-
inﬂammatory, anticancer, and antimicrobial activities. The
antibacterial activity of the phenolic fraction of N. sativa oil
was ﬁrst reported by Toppozada et al.7 However, its activ-
ity against H. pylori was described only 40 years later (in
2005) by O’Mahony et al,8 who found that the hot aqueous
extract ofN. sativa exerted 100%bactericidal activity againstH.
pylori when tested against a standard American Type Culture
Collection strain and six different clinical isolates. Neverthe-
less, the minimum bactericidal concentration (MBC) was not
reported in that study because only one concentration of the
direct aqueous extract was used. Later, Zaidi et al9 examined
the activity of N. sativa by using seven H. pylori clinical iso-
lates and different concentrations of 70% alcoholic extract
of N. sativa (7.8g/mL, 15.6g/mL, 31.2g/mL, 62.5g/mL,
125g/mL, 250g/mL, and 500g/mL). It was demonstrated
that the extracts ofN. sativa completely inhibited the growth of
H. pyloriat 500g/mL, and that theMBCwas 62.5g/mLagainst
six isolates and 125g/mL against one isolate. Furthermore,
Hajimahmoodi et al10 tested themethanolic extract ofN. sativa
against 12 clinical isolates of H. pylori and found that the min-
imum inhibitory concentration (MIC) against three, eight, and
one isolateswas 128g/mL, 256g/mL, and 512g/mL, respec-
tively. This difference in the inhibitory concentrations among
these three above-mentioned studies might be attributable to
the difference in the solvent used and the extraction proce-
dure used. Nevertheless, despite this varying MBC or MIC, it is
clear that N. sativa exerts an appreciable anti-H. pylori activity,
and therefore, can be considered for testing in human volun-
teers.
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Different active components ofN. sativahave been reported
to exhibit potent activity against H. pylori-associated infec-
tions, although they have not been tested in the H. pylori
infection model. The alcoholic extract of N. sativa was
observed to show potent antiulcer activity in two different
ulcer models such as pyloric ligation and aspirin-induced gas-
tric mucosal damage.11 In addition, N. sativa oil was proposed
to exert a hypogastrinemic effect by activating guanylate
cyclase, leading to an increased intracellular cGMP and a sub-
sequent decrease in intracellular Ca2+, and gastrin secretion.12
Furthermore, thymoquinone, an active ingredient isolated
from N. sativa, was reported to exhibit antioxidant, anti-
inﬂammatory, andanticancer activities.13 AsH. pylori infection
can lead to ulcer, inﬂammation, and gastric cancer, treatment
using N. sativa may result in the eradication of H. pylori infec-
tion as well as the disease caused by the organism.
Salem et al14 tested the efﬁcacy of N. sativa seeds against
H. pylori infection in 88 patients with nonulcer dyspepsia,
and compared it with that of standard triple therapy. It was
observed that N. sativa, administered as 500-mg capsules con-
taining ground N. sativa seeds, eradicated H. pylori infection.
The eradication rates achieved by triple therapy, 1 g, 2 g, and
3g of N. sativa were 82.6%, 47.6%, 66.7%, and 47.8%, respec-
tively, and no statistically signiﬁcant difference was observed
between the eradication rates achieved using triple therapy
and 2g of N. sativa. However, the study did not explain about
the lesser efﬁcacy ofN. sativa at higher doses. In a comment on
their own article in Alimentary Pharmacology & Therapeutics,15
May et al16 indicated that they had observed an interpretable
difference in the treatment outcome between the H. pylori-
positive and -negative patients when treated with a ﬁxed
combination of 90mg of peppermint oil and 50mg of caraway
oil. However, the drawback in their study was that only 25%
of the patients (24 out of 96) were H. pylori positive and the
remaining 75% of the patients were H. pylori negative, thus
necessitating a study with a larger population to prove its
effectiveness. Furthermore, in their study, caraway oil was
used in combination with peppermint oil, and hence, the clear
role of caraway was not completely proven because pepper-
mint oil was also noted to exhibit anti-H. pylori activity.
5. Mastic gum
Mastic gum is a natural resin that is excreted from the trunk
and branches of the mastic bush (Pistacia lentiscus). Huwez
et al17 were the ﬁrst to report on the bactericidal effect of
mastic gum against H. pylori, and observed that crude mas-
tic gum could kill H. pylori at a concentration of 0.06mg/mL,
regardless of whether the organism was sensitive or resis-
tant to metronidazole. In addition, they also reported that
the lowest concentration tested, 0.0075mg/mL, could signif-
icantly inhibit the growth of H. pylori. This report was followed
by a study by Marone et al,18 who found that 50% and 90%
of H. pylori strains were inhibited at a mastic gum concentra-
tion of 125g/mL and 500g/mL, respectively. In addition, the
morphological changes assessed through transmission elec-
tron microscopy were also reported, and it was noted that at
a sub-MBC concentration, blebbing, morphological abnormal-
ities, and cellular fragmentation were observed. These studiesIntegr Med Res ( 2 0 1 4 ) 111–118
were further validated by Loughlin et al19 through in vitro
susceptibility testing and in vivo H. pylori eradication using
speciﬁc-pathogen-free CD1 mice infected with H. pylori. In
accordance with the previous reports, Loughlin et al19 found
that mastic gum exhibited good MIC and MBC against H. pylori
SS1, with values of 7.80mg/L and 31.25mg/L, respectively.
However, paradoxically,mastic gum failed to eradicateH. pylori
infection in the infected mice model and did not produce any
reduction in the bacterial load, although the mouse stomach
was immediately examined after 7 days of treatment. The
same year, Bebb et al20 reported the role of mastic gum in
H. pylori eradication in nine patients with H. pylori infection
and proved the inefﬁciency of mastic gum in clearing H. pylori
infections. In their study, mastic gum was administered at a
high dose of 1 g four times a day for 14 days, and at the end
of the treatment regime, all patients were still found to be H.
pylori positive.
Regardless of the contradictory reports on the activity of
mastic gum, research on its anti-H. pylori activity has contin-
ued. For instance, Paraschos et al21 performed both in vivo and
in vitro assays of the anti-H. pylori activity of mastic gum. Their
study differed from the previous studies in that the treatment
regime used was longer (3 months, as opposed to 1 week in
the study by Loughlin et al19) and the insoluble polymers were
removed from mastic gum to ameliorate solubility. Adminis-
tration of mastic gum at a concentration of 0.75mg/day led
to an approximately 30-fold reduction in H. pylori colonization
in the infected mice; however, this eradication did not atten-
uate chronic inﬂammatory inﬁltration and chronic gastritis.
Furthermore, the acidic and neutral fractions of mastic gum
were tested for anti-H. pylori activity in vitro, and it was found
that the acid fraction was the most active (MBC=0.139mg/mL)
and that isomasticadienolic acid was the most active iso-
lated compound (MBC=0.202mg/mL). These results show that
administration of mastic gum may be effective in reducing
H. pylori colonization, and that the major triterpenic acids in
the acidic fraction may be responsible for such an activity. In
another study, Dabos et al22 administered two different doses
of mastic gum (350mg and 1.0 g) three times a day for 14 days,
and noted that the H. pylori was eliminated at a rate of 30.8%
and 38.5%, respectively. However, the authors had used only
a small sample size (n=13 participants) and did not include a
detailed description of the difference between their study and
the report by Bebb et al.20
6. Broccoli
Broccoli is an edible green plant in the cabbage family, whose
large ﬂower head is used as a vegetable. Fahey et al23 isolated
sulforaphane, a glucosinolate precursor, from broccoli and
broccoli sprouts, and showed that the isolated compound was
effective against three reference strains and 45 clinical isolates
of H. pylori with an MIC of <4g/mL for 90% of the strains. In
addition, the experiment was also performed at different pH
levels, and it was observed that the MIC remained unaltered
at the neutral pH and at a pH of 5.8. As the pH of 5.8 closely
reﬂects the gastric juxta mucosal pH, it can be concluded that
sulforaphane could retain the in vivo biological activity against
H. pylori. Furthermore, the bactericidal activity of sulforaphane
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as also conﬁrmed by brieﬂy exposing the human epithe-
ial cell line (HEp-2) infected with H. pylori to sulforaphane.
n complementary experiments, sulforaphane concentration
ve timeshigher than theMICwas found to kill all the intracel-
ular H. pylori in forestomach tumors in ICR mice in 4–8hours.
oreover, sulforaphane was noted to possess antioxidative,
nti-inﬂammatory, and anticancer activities,24 and was also
eported to inhibit urease activity.23 Later, Moon et al25 per-
ormed a study to determine the anti-H. pylori activity by
sing chloroform, methanol, ethylacetate, butanol, and water
xtracts. Among the different extracts tested, the methano-
ic extract exerted the most potent anti-H. pylori activity (as
ompared to ethyl acetate and butanol extracts), whereas the
queous extract did not produce any activity. The anti-H. pylori
ctivity of the extracts was observed to be in the following
rder: chloroform > hexane > ethyl acetate > butanol > crude
ethanol extracts.
A pilot study conducted by Galan et al26 using nine patients
evealed that H. pylori was eradicated in 33.33% of the patients
ho consumed broccoli sprouts at a dose of 14 g, 28 g, or 56 g
wice a day for 7 days. When a stool antigen test was con-
ucted, it was found that at the end of 7 days, seven out of
patients (78%) remained H. pylori negative; however, at the
nd of the 35th day, six out of nine patients (67%) were H.
ylori negative, indicating that there is a chance of recurrence
o infection. Furthermore, immunostaining for the detection
f H. pylori in the biopsy taken from these patients indicated
hat only three out of nine patients were completely negative
or H. pylori, exhibiting H. pylori eradication in 33% of the cases.
n another study, the participants were made to consume 10
ervings of 130 g of fresh juvenile broccoli tips to determine its
nti-H. pylori activity.27 The urea broth test carried out prior to
nd after consumption indicated no difference, suggesting no
ctivity against H. pylori. However, a major drawback of this
tudy was that only ﬁve volunteers received broccoli for only
short period of 3 days.
Similar results were also observed by Yanaka et al,28 who
creened H. pylori stool antigen after administering 70 g of
roccoli sprouts/day containing 420mol of Sulforaphane pre-
ursor to participants for 8 weeks and found that 32% (8 of 25)
f the participants were H. pylori negative at 8 weeks. How-
ver, most of the participants were noted to be positive for
. pylori after 6 months of intervention, whereas two partici-
ants were negative for H. pylori, thus indicating that broccoli
prout treatment reduced H. pylori colonization, but did not
ompletely eradicate H. pylori.28 In the same study, broccoli
prouts were homogenized and administered to C57BL/6 mice
∼3mol/mouse/day of glucoraphanin equivalents), which
esulted in decreased corpus gastritis and protected the mice
romgastricmucosal inﬂammation. This ﬁnding suggests that
ulforaphanemaynot only have a direct antibacterial effect on
. pylori colonization, but its primary effect may also be via the
pregulation of the host’s systemic protection against oxida-
ive stress and inﬂammation, resulting in an initial decrease
n H. pylori colonization.
Although varying results have been reported, it is worth
oting that sulforaphane has been found to exert a potent
nti-H. pylori activity and inhibit H. pylori urease, along with
ntioxidative, anti-inﬂammatory, and anticancer activities.
ence, instead of administering alone, testing this isolated115
compound in combination may be beneﬁcial in obtaining
more convincing results in clinical settings. Furthermore,
although all the results are not completely justiﬁable to con-
clude that broccoli consumption has therapeutic beneﬁt, the
available studies underline that regular consumption of broc-
coli could improve the endurance of the gastrointestinal
system against H. pylori-like infections.
7. Cranberry
Cranberries consist of nearly 90% water and are a great source
of dietary ﬂavonoids, including anthocyanins and proantho-
cyaninswith high antioxidant potential andwell-documented
health beneﬁts.29 Zhang et al30 published the ﬁrst clinical
report on the efﬁcacy of consuming cranberry juice in sup-
pressing H. pylori infection. In the double-blind, randomized
placebo-controlled trial, 97 of the 189 H. pylori-positive indi-
viduals received 250mL of cranberry juice and 92 participants
received placebo twice a day for 90 days. The efﬁcacy assessed
at 45 days and 90 days showed that 14.43% (14 of 97) and 5.44%
(5 of 92) of theparticipants in the cranberry andplacebo groups
were H. pylori negative, respectively. Although 14 participants
were found to be H. pylori negative at both the intervention
points, it is worth noting that only 11 participants commonly
remainedH. pylorinegative, indicating that the other threepar-
ticipants might have developed recurrence of infection; thus,
the efﬁcacy of cranberry against H. pylori infection is question-
able. In addition, three participants who were H. pylori positive
at 35 days were negative at 90 days, suggesting that a longer
intervention may also prove effective in eradicating H. pylori
infection. However, the density and intensity of the bacteria in
the gastric mucosa of the 13c-urea-positive individuals were
not analyzed, and hence, the actual H. pylori status is unclear;
however, the biopsy of the stomach and a probable H. pylori
identiﬁcation might have provided an added advantage. Fur-
thermore, the study failed to analyze the H. pylori status of the
participants who were negative for the bacterium after a spe-
ciﬁc window period, and no subsequent follow-up was carried
out to check the H. pylori status.
As an alternative to the administration of cranberry as a
monotherapy, Shmuely et al31 conducted a double-blind ran-
domized clinical study to test the additive effect of cranberry
juice along with a triple therapy consisting of omeprazole,
amoxicillin, and clarithromycin (OAC). The OAC therapy was
administered during the 1st week, followed by cranberry
administration for 2 weeks, and it was found that 95.2% and
73.9% of the female and male patients were H. pylori negative,
respectively. However, no signiﬁcant difference was observed
among the male patients when the cranberry–OAC group was
compared with the placebo or nonplacebo groups, indicat-
ing that the additive therapy was only effective in female
patients. In another study testing the additive effect along
with Lactobacillus sp., it was noted that the intake of lactobacil-
lus or cranberry could reduce H. pylori infection in children
positive for the bacterium; however, no additional effect was
noticed when lactobacillus and cranberry were administered
in combination.32
Furthermore, Burger et al33,34 reported the antiadhe-
sive property of a high molecular weight constituent from
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cranberry. In their two consecutive studies, it was shown that
a high molecular weight constituent from cranberry could
interfere with the sialic-acid-speciﬁc adhesion of H. pylori
to gastric mucus. In addition to anti-H. pylori activity, Chat-
terjee et al35 reported that berry extract could increase the
susceptibility of H. pylori to the antibiotic clarithromycin. An
additive inhibitory effect was noted when clarithromycin was
used in combinationwith different concentrations of the berry
extract, thus indicating the potential antibacterial activity of
the berry extract used individually or in combination with
antibiotics against H. pylori. Matsushima et al36 found that
the polyphenolic compounds from cranberry could inhibit H.
pylori proliferation and induce morphological changes leading
to bacteriostatic activity. Nevertheless, although the overall
efﬁcacy of cranberry appears to be appreciable, further studies
on large populations are warranted to justify its efﬁcacy.36
8. Prunus mume
P. mume, commonly known as the Chinese plum or Japanese
apricot, is related to both the plum and apricot trees.
Syringaresinol, an active compound isolated from P. mume,
was shown to inhibit more than 90% motility of H. pylori at
a concentration of 500g/mL, and exhibited an IC50 value of
50g/mL. As motility is essential for H. pylori migration and
colonization, the inhibition of motility will lead to reduced
colonization of the bacterium in the gastric mucosa.37 In a
H. pylori-infected Mongolian gerbils model, it was observed
that consumptionof P.mume concentrate signiﬁcantly reduced
the urease A expression in the infected stomach, indicating
the decrease in H. pylori infection.38 Furthermore, Enomoto et
al39 demonstrated the preventive effect of P. mume on chronic
atrophic gastritis by inhibiting H. pylori infection and reducing
active mucosal inﬂammation. In their study, the volunteers
received either dried or pickled P. meme, and at the end of the
interventional period, histological examination of the biopsy
samples from the nonelderly individuals (<65 years) showed
that the high-intake group (X3 JA daily) had signiﬁcantly
less H. pylori load, neutrophil inﬁltration, and mononuclear
inﬁltration in the gastric mucosa, when compared with the
low-intake group (X3 JA daily).
9. Cinnamon
Cinnamon is a spice obtained from the inner bark of several
trees from the genus Cinnamomum. Tabak et al40 reported that
ethanolic and methylene chloride extracts of cinnamon could
inhibit both H. pylori and free urease. In addition, O’Mahony
et al8 demonstrated that cinnamon has bactericidal activities
against H. pylori; however, the hot aqueous extract of cinna-
mon used in their study failed to exhibit total inhibition of the
bacterial growth. Furthermore, in a controlled trial carried out
by Nir et al,41 it was found that cinnamon extract, as a sin-
gle agent, at a higher concentration of 80mg/day (twice daily
for 4 weeks) failed to eradicate H. pylori infection. However,
the study was conducted in a smaller group of volunteers (15
people). Although these ﬁndings show that cinnamon extract
can be tolerated well without any side effects, they cannot beIntegr Med Res ( 2 0 1 4 ) 111–118
completely justiﬁed owing to the lack of clinical studies in a
large population.
10. Propolis
Propolis is a resinous mixture that was collected from tree
buds, sap ﬂows, or other botanical sources by honey bees, and
it was widely reported to induce biological activities includ-
ing antibacterial, emollient, immunomodulator, anti-allergic,
antioxidant, and anticancer activities.42 In 1998, Hashimoto
et al43 ﬁrst reported the anti-H. pylori activity of propolis,
and later in 2001 Banskota et al44 reported that labdane-type
diterpenes and some of the prenylated phenolic compounds
isolated frompropolis exhibit anti-H. pyloriactivity. In 2003 and
2005, Boyanova et al45,46 reported that 30% ethanolic extract of
propolis exerted dose-dependent anti-H. pylori activity against
38 and 94 different clinical isolates of H. pylori, respectively. A
similar in vitro study by Nostro et al47,48 showed that propolis
has an MIC90 value of 0.075mg/mL, using 11 clinical isolates
of H. pylori, and in the subsequent year a report from the same
group indicated that propolis in combination with the antibi-
otic clarithromycin also exerted good anti-H. pylori activity.
Basedon these in vitro reports, theﬁrst clinical report onpropo-
lis was described in the study by Coelho et al,49 where 18 H.
pylori-positive patents (11 females and 7 males) were orally
administered with 20 drops of alcoholic preparation of propo-
lis three times a day for 1 week. Forty days later, the clinical
intervention noted that 83% of the patients remained posi-
tive for H. pylori, leading to the conclusion of the minimal
effectiveness of propolis in eliminating H. pylori infection in
human volunteers.49 However, this warrants a more detailed
study with comparative standard therapy and different doses
with longer periods of treatment and the involvement of a
larger number of participants. Recently, Cui et al50 reported
that caffeic acid phenethyl ester, an active compound from
propolis, can competitively inhibit H. pylori peptide deformy-
lase (HpPDF) with an IC50 value of 4.02M. Because HpPDF
catalyzes the removal of the formyl group from theN terminus
of nascent polypeptide chains and this process was essen-
tial for H. pylori survival, inhibiting HpPDF will be effective in
anti-H. pylori therapy.
11. Curcumin
Curcumin is a diarylheptanoid, and it is the principal cur-
cuminoid of the popular south Asian spice turmeric, which
is a member of the Zingiberaceae family. Turmeric’s other two
curcuminoids are desmethoxycurcumin and bisdesmethoxy-
curcumin. The curcuminoids are phenolic in nature and
responsible for the yellow color of turmeric. When curcumin
was tested against 19 strains of H. pylori, it inhibited the
growth of all strains with an MIC range of 6.25–50g/mL.51
Curcumin was also reported to inhibit shikimate dehydroge-
nase, an enzyme responsible for the biosynthesis of aromatic
amino acids (phenylalanine, tyrosine, and tryptophan) in H.
pylori. Inhibition of this enzyme is of particular importance
in antimicrobial drug therapies, because human beings are
not dependent on this enzyme of amino acid synthesis, which
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akes the inhibition of shikimate dehydrogenase toxic only
o pathogens and not to the host.52 A study by De et al53 tested
he anti-H. pylori activity of curcumin against 65 clinical iso-
ates in in vitro and in vivo usingH. pylori-infected C57BL/6mice
odel. The in vitro results showed that the MIC of curcumin
anged from 5g/mL to 50g/mL, proving its effectiveness in
. pylori inhibition. In mice, curcumin is shown to be highly
ffective in eradication of H. pylori as well as in restoration of
. pylori-induced gastric damage.53 Although various in vitro
nd in vivo reports are available on the effectiveness of cur-
umin against H. pylori, only one clinical study using curcumin
as described the ineffectiveness of curcumin in eliminating
. pylori infection or its associated symptoms. In this study,
nly 12% (3 out of 25) of the patients were H. pylori-negative
t the end of the treatment regime using 30g curcumin for 7
ays.54
2. Conclusion
mong the published clinical trials obtained from the
atabases—focusing on H. pylori (219), olive oil (138), N. sativa
6), mastic gum (1), broccoli (52), cranberry (54), P. mume (3),
innamon (26), propolis (0), and curcumin (1)—it is surpris-
ng to note that to date, there have been no registered trials
nalyzing the activity of these natural products except one
n cranberry against H. pylori. Although these natural prod-
cts with proven health beneﬁts have been used since time
mmemorial for alleviating various gastrointestinal tract dis-
ases, their mechanism of action is not well established.
oreover, studies on the safety and efﬁcacy of the active com-
ounds isolated from these products are extremely important
n our ongoing efforts to formulate these compounds and
ake them available for further clinical use.
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